| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_730640d4245582eb94f517443a707e05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fa013e4c0aade61a190727bf285b78f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_592abc2fb2f85f1a654dcca28a0dfaf8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f0752ae37470d38fb00b638f45de8f59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e396c20c8cdf4f40a24cafb819cbb27c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2009-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4e7611b55b19d336a01890fd21726e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0d0ed579cea82d553937ba2bb07b314
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e12f67827500c85454a3f1630ebec766
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1edd1459b18e7f13d4ded3417a8f3d5 |
| publicationDate |
2010-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010083880-A1 |
| titleOfInvention |
Prognosis of breast cancer patients by monitoring the expression of two genes |
| abstract |
The present invention relates to the expression of two genes, CyclinG2 and Sharp1, which correlates with prognosis in individuals having breast cancer. Specifically, this invention provides a method to stratify samples from breast cancer patients in a high or low recurrence risk in the years following primary tumor removal. This classification can be achieved through the analysis of protein or mRNA expression levels for the two identified genes. The invention also illustrates how CyclinG2 and Sharp1 have been identified in mammary cancer cell lines and validated in a large cohort of human patients as powerful metastasis predictors. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9726661-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014006227-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10969380-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020247861-A1 |
| priorityDate |
2009-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |